- Home
- ESS vs INSM Comparison
ESS vs INSM Comparison
Compare ESS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- INSM
- Stock Information
- Founded
- ESS 1971
- INSM 1988
- Country
- ESS United States
- INSM United States
- Employees
- ESS N/A
- INSM N/A
- Industry
- ESS Real Estate Investment Trusts
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- ESS Real Estate
- INSM Health Care
- Exchange
- ESS Nasdaq
- INSM Nasdaq
- Market Cap
- ESS 18.3B
- INSM 19.1B
- IPO Year
- ESS 1994
- INSM 2000
- Fundamental
- Price
- ESS $286.72
- INSM $99.11
- Analyst Decision
- ESS Hold
- INSM Strong Buy
- Analyst Count
- ESS 19
- INSM 17
- Target Price
- ESS $309.33
- INSM $108.07
- AVG Volume (30 Days)
- ESS 437.8K
- INSM 5.0M
- Earning Date
- ESS 07-29-2025
- INSM 08-07-2025
- Dividend Yield
- ESS 3.58%
- INSM N/A
- EPS Growth
- ESS 27.78
- INSM N/A
- EPS
- ESS 10.45
- INSM N/A
- Revenue
- ESS $1,861,154,000.00
- INSM $381,030,000.00
- Revenue This Year
- ESS $3.97
- INSM $28.03
- Revenue Next Year
- ESS $3.85
- INSM $120.54
- P/E Ratio
- ESS $27.44
- INSM N/A
- Revenue Growth
- ESS 9.74
- INSM 20.77
- 52 Week Low
- ESS $243.85
- INSM $60.40
- 52 Week High
- ESS $317.73
- INSM $106.83
- Technical
- Relative Strength Index (RSI)
- ESS 53.94
- INSM 62.52
- Support Level
- ESS $281.42
- INSM $95.27
- Resistance Level
- ESS $288.96
- INSM $98.53
- Average True Range (ATR)
- ESS 6.74
- INSM 2.77
- MACD
- ESS 0.09
- INSM -1.45
- Stochastic Oscillator
- ESS 68.48
- INSM 34.45
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 257 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.